Last reviewed · How we verify
SOF+PEG+RBV
At a glance
| Generic name | SOF+PEG+RBV |
|---|---|
| Also known as | GS-7977, PSI-7977, Sovaldi®, Pegasys®, Copegus® |
| Sponsor | Humanity and Health Research Centre |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (PHASE2)
- Re-treatment of HCV Following DAA Failure (NA)
- Directly Observed Therapy for HCV in Chennai, India (PHASE2)
- Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4 (PHASE1,PHASE2)
- Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study (PHASE2)
- Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects (PHASE2)
- Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection (PHASE2)
- Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SOF+PEG+RBV CI brief — competitive landscape report
- SOF+PEG+RBV updates RSS · CI watch RSS
- Humanity and Health Research Centre portfolio CI